FIELD: medicine, immunology. SUBSTANCE: method involves administration of monoclonal antibodies raised against surface protein 4-1BB of murine cells to host that induces suppression of the first and the second humoral response. Invention comprises two monoclonal antibodies. The advantage of invention involves development of novel approach to immusuppression in cancer therapy. EFFECT: improved methods and compositions. 20 cl, 14 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| SOLUBLE MUTANT CTLA4 MOLECULES | 1998 |
|
RU2235555C2 |
| SOLUBLE MUTANT CTLA4 AND USES THEREOF | 2001 |
|
RU2283847C2 |
| METHODS FOR TREATMENT OF RHEUMATIC DISEASES BY USING SOLUBLE CTLA4 | 2001 |
|
RU2287340C2 |
| SYNERGIC METHODS AND COMPOSITIONS FOR CANCER TREATMENT | 2001 |
|
RU2264217C2 |
| USE OF INHIBITORS OF IMMUNE CONTROL POINTS IN NEW GROWTHS OF CENTRAL NERVOUS SYSTEM | 2015 |
|
RU2726996C1 |
| TREATING LUNG CANCER BY COMBINATION OF ANTI-PD-1 AND OTHER ANTI-CANCER AGENTS | 2015 |
|
RU2695332C2 |
| ANTIBODIES AGAINST IL-7R ALPHA SUBUNIT AND THEIR USE | 2020 |
|
RU2811912C2 |
| CARDIOVASCULAR DISEASE THERAPY WITH USING SOLUBLE CTLA4 | 2004 |
|
RU2353384C2 |
| METHOD AND COMPOSITIONS FOR CELL IMMUNOTHERAPY | 2013 |
|
RU2700765C2 |
| MOLECULES WHICH BIND TO 4-1BB | 2011 |
|
RU2710717C2 |
